JP2023502843A5 - - Google Patents
Info
- Publication number
- JP2023502843A5 JP2023502843A5 JP2022519139A JP2022519139A JP2023502843A5 JP 2023502843 A5 JP2023502843 A5 JP 2023502843A5 JP 2022519139 A JP2022519139 A JP 2022519139A JP 2022519139 A JP2022519139 A JP 2022519139A JP 2023502843 A5 JP2023502843 A5 JP 2023502843A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- fusion polypeptide
- cancer
- amino acid
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1913804.9 | 2019-09-25 | ||
| GB201913804A GB201913804D0 (en) | 2019-09-25 | 2019-09-25 | Fusion polypeptides |
| PCT/GB2020/052328 WO2021058973A1 (en) | 2019-09-25 | 2020-09-25 | Il-15 fusion peptides used to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502843A JP2023502843A (ja) | 2023-01-26 |
| JP2023502843A5 true JP2023502843A5 (enExample) | 2023-09-28 |
Family
ID=68425465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519139A Pending JP2023502843A (ja) | 2019-09-25 | 2020-09-25 | 癌を処置するために使用されるｉｌ－１５融合ペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220372097A1 (enExample) |
| EP (1) | EP4034552A1 (enExample) |
| JP (1) | JP2023502843A (enExample) |
| CN (1) | CN114651014A (enExample) |
| AU (1) | AU2020351698A1 (enExample) |
| CA (1) | CA3155100A1 (enExample) |
| GB (1) | GB201913804D0 (enExample) |
| IL (1) | IL291560A (enExample) |
| WO (1) | WO2021058973A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| GB9614871D0 (en) | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
| US20070160578A1 (en) * | 2005-12-14 | 2007-07-12 | The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services | Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes |
| GB0915519D0 (en) | 2009-09-04 | 2009-10-07 | King S College London | Ntithrombotic compounds |
| WO2012054509A2 (en) * | 2010-10-22 | 2012-04-26 | Dana-Farber Cancer Institute, Inc. | Discovery of regulatory t cells programmed to suppress an immune response |
| WO2018161026A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il15 compositions and methods for immunotherapy |
| WO2019006472A1 (en) * | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| CA3086040A1 (en) * | 2017-12-19 | 2019-06-27 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| AU2019228381B2 (en) * | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
| CA3090407A1 (en) * | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
-
2019
- 2019-09-25 GB GB201913804A patent/GB201913804D0/en not_active Ceased
-
2020
- 2020-09-25 CA CA3155100A patent/CA3155100A1/en active Pending
- 2020-09-25 AU AU2020351698A patent/AU2020351698A1/en not_active Abandoned
- 2020-09-25 US US17/762,358 patent/US20220372097A1/en not_active Abandoned
- 2020-09-25 WO PCT/GB2020/052328 patent/WO2021058973A1/en not_active Ceased
- 2020-09-25 CN CN202080067412.0A patent/CN114651014A/zh active Pending
- 2020-09-25 JP JP2022519139A patent/JP2023502843A/ja active Pending
- 2020-09-25 EP EP20793045.4A patent/EP4034552A1/en not_active Withdrawn
-
2022
- 2022-03-21 IL IL291560A patent/IL291560A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240066096A1 (en) | pHLIP® peptide mediated epitope tethering at cell surfaces | |
| JP4480580B2 (ja) | Ｗｔ１置換型ペプチド | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| CA2641565A1 (en) | Nel-related proteins type 1 and 2, and polynucleotides encoding them | |
| NZ281409A (en) | Medicaments for cancer treatment using peptides based on a 9 AA epitiope derived from mage -3 that induces ctls | |
| JP2016538829A (ja) | 低密度リポタンパク質受容体をコードするポリヌクレオチド | |
| JP2015517995A (ja) | 美容タンパク質およびペプチドの産生のための修飾ポリヌクレオチド | |
| EP2118128B1 (en) | Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1 | |
| RU2020128838A (ru) | Композиции и способы для индуцирования передачи сигнала белка, содержащего трехсторонний мотив, 16 (trim16) | |
| AU9084601A (en) | G-csf analog compositions and methods | |
| JP2008530975A5 (enExample) | ||
| JP2023502843A5 (enExample) | ||
| JP2019515653A5 (enExample) | ||
| JP2010514669A5 (enExample) | ||
| US8309096B2 (en) | Fusion protein | |
| CA2432971A1 (en) | Polypeptides | |
| US20200062811A1 (en) | Yap protein inhibiting polypeptide and application thereof | |
| US20170319648A1 (en) | High activity tumour inhibitor and preparation method and use thereof | |
| CN100467063C (zh) | 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用 | |
| RU2004122084A (ru) | Пептиды для лечения рака, ассоциированного с папилломавирусом (hpv) человека, и других эпителиальных опухолей | |
| JP2022501046A5 (enExample) | ||
| RS58313B1 (sr) | Himerni proteini na bazi hpv/cyaa i njihove upotrebe u indukovanju imunskih odgovora na hpv infekciju i hpv-indukovane poremećaje | |
| CN117797253A (zh) | 一种能扩展t细胞抗原表位的肿瘤疫苗及其制备方法 | |
| CN110857315A (zh) | 一种治疗肿瘤的多肽药物、衍生物及其使用方法 | |
| CN108250277B (zh) | 微小rna31前体编码多肽的截短体在制备免疫调节药物中的应用 |